Dynamic modeling for pandemic influenza

Expert Review of Vaccines

Volumn 11, Issue 5, 2012, Pages 543-546

  Postma, Maarten J ^a  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; INFLUENZA VACCINE; PNEUMOCOCCUS VACCINE;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL VIRULENCE; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DEVELOPED COUNTRY; DEVELOPING COUNTRY; DISEASE SEVERITY; DISEASE TRANSMISSION; DYNAMICS; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; MIXED INFECTION; MODEL; NETHERLANDS; NONHUMAN; NOTE; PANDEMIC INFLUENZA; PRIORITY JOURNAL; SECONDARY INFECTION; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; VACCINATION; VIRUS VIRULENCE;

EID: 84862537845     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.12.30     Document Type: Note

References (23)

1. Postma MJ, Milne G, Nelson EA et al.; PI Group. Pharmaceutical interventions for mitigating an influenza pandemic: modeling the risks and health-economic impacts. Expert Rev. Anti Infect. Ther. 8(12), 1431-1439 (2010
2. Lugnér AK, Postma MJ. Investment decisions in influenza pandemic contingency planning: cost-effectiveness of stockpiling antiviral drugs. Eur. J. Public Health 19(5), 516-520 (2009
3. Mylius SD, Hagenaars TJ, Lugnér AK, Wallinga J. Optimal allocation of pandemic influenza vaccine depends on age, risk and timing. Vaccine 26(29-30), 3742-3749 (2008
4. Germann TC, Kadau K, Longini IM Jr, Macken CA. Mitigation strategies for pandemic influenza in the United States. Proc. Natl Acad. Sci. USA 103(15), 5935-5940 (2006
5. Meltzer MI, Cox NJ, Fukuda K. The economic impact of pandemic influenza in the United States: priorities for intervention. Emerging Infect. Dis. 5(5), 659-671 (1999
6. Chien YW, Levin BR, Klugman KP. The anticipated severity of a "1918-like" influenza pandemic in contemporary populations: the contribution of antibacterial interventions. PLoS ONE 7(1), e29219 (2012
7. Mylius SD, Hagenaars TJ, Lugnér AK, Wallinga J. Optimal allocation of pandemic influenza vaccine depends on age, risk and timing. Vaccine 26, 3742-3749 (2008
8. Anderson RM, May RM. Vaccination and herd immunity to infectious diseases. Nature 318(6044), 323-329 (1985
9. Ferguson NM, Cummings DA, Fraser C, Cajka JC, Cooley PC, Burke DS. Strategies for mitigating an influenza pandemic. Nature 442(7101), 448-452 (2006
10. de Vries R, Kretzschmar M, Schellekens JF et al. Cost-effectiveness of adolescent pertussis vaccination for The Netherlands: using an individual-based dynamic model. PLoS ONE 5(10), e13392 (2010
11. Hubben G, Bootsma M, Luteijn M et al. Modelling the costs and effects of selective and universal hospital admission screening for methicillin-resistant Staphylococcus aureus. PLoS ONE 6(3), e14783 (2011
12. Baguelin M, Hoek AJ, Jit M, Flasche S, White PJ, Edmunds WJ. Vaccination against pandemic influenza A/H1N1v in England: a real-time economic evaluation. Vaccine 28(12), 2370-2384 (2010
13. Mossong J, Hens N, Jit M et al. Social contacts and mixing patterns releVant to the spread of infectious diseases. PLoS Med. 5(3), e74 (2008
14. Siddiqui MR, Edmunds WJ. Cost-effectiveness of antiviral s tockpiling and near-patient testing for potential influenza pandemic. Emerging Infect. Dis. 14(2), 267-274 (2008
15. Van Genugten ML, Heijnen ML, Jager JC. Pandemic influenza and healthcare demand in The Netherlands: scenario analysis. Emerging Infect. Dis. 9(5), 531-538 (2003
16. Postma MJ, Heijnen ML, Jager JC. Cost-effectiveness analysis of pneumococcal vaccination for elderly individuals in The Netherlands. Pharmacoeconomics 19(2), 215-222 (2001
17. Shapiro ED, Berg AT, Austrian R et al. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N. Engl. J. Med. 325(21), 1453-1460 (1991
18. Health Council. Commissie vaccinatie tegen influenza. Caccinatie bij een griep pandemie. Gezondheidsraad, Den Haag, The Netherlands (2000
19. Jit M, Brisson M. Modelling the epidemiology of infectious diseases for decision analysis: a primer. Pharmacoeconomics 29(5), 371-386 (2011
20. Postma MJ, Bos JM, Beutels P, Schilthuis H, Van den Hoek JA. Pharmaco-economic evaluation of targeted hepatitis A vaccination for children of ethnic minorities in Amsterdam (The Netherlands). Vaccine 22(15-16), 1862-1867 (2004
21. Van Hoek AJ, Gay N, Melegaro A, Opstelten W, Edmunds WJ. Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales. Vaccine 27(9), 1454-1467 (2009
22. Lugnér AK, Postma MJ. Mitigation of pandemic influenza: review of cost-effectiveness studies. Expert Rev. Pharmacoecon. Outcomes Res. 9(6), 547-558 (2009
23. Sander B, Nizam A, Garrison LP Jr, Postma MJ, Halloran ME, Longini IM Jr. Economic evaluation of influenza pandemic mitigation strategies in the United States using a stochastic microsimulation transmission model. Value Health 12(2), 226-233 (2009)